Uncategorized
Novelion posts $21.4 million quarterly loss
Novelion Therapeutics reported a GAAP net loss of $21.4 million in the second quarter of 2017 compared with a GAAP net loss of $5.1 million in the second quarter of 2016, according to a press release.Research and development costs were $10.8 million in 2017’s second quarter compared with $2.9 million in 2016, while total operating expenses increased from $7.4 million in the second quarter of 2016 to $38.4 million in the same period of 2017.